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Abstract
Background: A reciprocal relationship between bone and fat development in osteoporosis is
clinically well established. Some of the key molecular regulators involved in this tissue replacement
process have been identified. The detailed mechanisms governing the differentiation of
mesenchymal stem cells (MSC) – the key cells involved – are however only now beginning to
emerge. In an attempt to address the regulation of the adipocyte/osteoblast balance at the level of
gene transcription in a comprehensive and unbiased manner, we performed a large-scale gene
expression profiling study using a unique cellular model, human multipotent adipose tissue-derived
stem cells (hMADS).
Results: The analysis of 1606 genes that were found to be differentially expressed between
adipogenesis and osteoblastogenesis revealed gene repression to be most prevalent prior to
commitment in both lineages. Computational analyses suggested that this gene repression is
mediated by miRNAs. The transcriptional activation of lineage-specific molecular processes in both
cases occurred predominantly after commitment. Analyses of the gene expression data and
promoter sequences produced a set of 65 genes that are candidates for genes involved in the
process of adipocyte/osteoblast commitment. Four of these genes were studied in more detail:
LXRα and phospholipid transfer protein (PLTP) for adipogenesis, the nuclear receptor COUP-TF1
and one uncharacterized gene, TMEM135 for osteoblastogenesis. PLTP was secreted during both
early and late time points of hMADS adipocyte differentiation. LXRα, COUP-TF1, and the
transmembrane protein TMEM135 were studied in primary cultures of differentiating bone
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corresponding lineages.
Conclusion: Our results reveal gene repression as a predominant early mechanism before final
cell commitment. We were moreover able to identify 65 genes as candidates for genes controlling
the adipocyte/osteoblast balance and to further evaluate four of these. Additional studies will
explore the precise role of these candidate genes in regulating the adipogenesis/osteoblastogenesis
switch.
Background
That the decrease in bone volume associated with oste-
oporosis is accompanied by an increase in marrow adi-
pose tissue is clinically well known [1]. Pharmacological
inhibition of this tissue replacement process could pro-
vide a novel mode of treatment for this disorder. A
rational approach to drug development requires knowl-
edge of the underlying molecular mechanisms. For both
adipogenesis and osteoblastogenesis, many key regulators
have been identified using established cell model systems.
The detailed mechanisms that control the differentiation
of mesenchymal stem cells (MSC) – the key cell type
involved – are however only beginning to emerge.
Adipogenesis is a highly regulated process in which a
coordinated cascade of transcription factors leads to the
formation of mature adipocytes [2,3]. This cascade begins
with the transient expression of CCAAT/enhancer binding
protein β (C/EBPβ) and C/EBPδ which activate C/EBPα
and peroxisome proliferator-activated receptor γ (PPARγ).
C/EBPα and PPARγ together coordinate the expression of
adipogenic genes underlying the phenotype of terminally
differentiated adipocytes. This terminal differentiation is
characterised by the induction of genes including glycerol-
3-phosphate dehydrogenase (GPDH), hormone-sensitive
lipase (HSL), fatty acid synthase (FASN), fatty acid bind-
ing proteins (FABPs), perilipin (PLIN), and the produc-
tion and secretion of adipokines such as leptin (LEP),
adiponectin (ADIPOQ), adipsin (CFD), tumor necrosis
factor alpha (TNFα), visfatin (NAMPT) and retinol bind-
ing protein 4 (RBP4). Additional transcription factors,
such as sterol-regulatory element binding transcription
factor 1 (ADD1/SREBP1) can further modulate this termi-
nal differentiation process [3].
Osteoblastogenesis is also a highly coordinated process
and is initiated by the transcription factors runt-related
transcription factor 2 (RUNX2) and osterix (OSX), whose
expression is regulated by β-catenin, the homeobox pro-
tein MSX2, and a transcriptional coactivator with PDZ-
binding motif (TAZ) coactivating CBFA1 and repressing
PPARγ [4,5]. Bone morphogenetic proteins (BMPs) pro-
mote bone formation by stimulating the proliferation and
differentiation of osteoblasts [6]. BMPs elicit their cellular
effects via specific type I and II serine/threonine receptors
[7]. This cascade leads to the terminal osteoblast pheno-
type that is characterised by calcification of the extracellu-
lar matrix (ECM). The genes involved in this
mineralization process include noggin (NOG), osteonec-
tin (SPARC), osteoprotegerin (OPG), collagens COL1A1
and COL1A2, matrix Gla protein (MGP), matrilin-3
(MATN), and estrogen receptor 1 (ESR1) which are differ-
entially expressed in the developing human bone [8-14].
Despite intensive research efforts focusing on the individ-
ual differentiation pathways, little is known about the
molecular mechanisms that drive final lineage commit-
ment. The small number of candidate genes identified to
date include MSX2 and C/EBPβ which are involved in the
reciprocal switch between adipocyte and osteoblast differ-
entiation [15,16], and FKBP5 which is up-regulated in a
differentiation-independent manner in mesenchymal lin-
eages [17]. These genes were identified either using estab-
lished cell lines or bone marrow and adipose tissue-
derived multipotent MSCs able to differentiate into mul-
tiple cell lineages including chondrocytes, osteoblasts and
adipocytes [18,19]. Both types of model systems have
associated advantages and disadvantages. Cell lines for
instance represent a single genetic background but are
karyotypically heterogeneous. Primary cells on the other
hand have normal karyotypes but are genetically hetero-
geneous since they are derived from multiple donors.
In an attempt to address the transcriptional regulation of
the adipocyte/osteoblast balance in a comprehensive and
unbiased manner we have applied large-scale gene expres-
sion profiling to a human multipotent adipose-derived
stem (hMADS) cell-derived cell line that exhibits a normal
karyotype, high self-renewal capacity and an ability to dif-
ferentiate into different cell types including adipocytes
and osteoblasts and to support in vivo regenerative proc-
esses [20-23]. We asked the question if the global expres-
sion profiles were different between the stages before and
after lineage commitment. In a first step we performed a
detailed characterization of the model and then used
microarrays and in-depth bioinformatics analyses to com-
prehensively study gene expression changes associated
with osteoblastogenic and adipogenic differentiation. For
both lineages genes and biological processes were found
to be predominantly down-regulated prior to commit-Page 2 of 14
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that this repression is mediated by miRNA. We further
identified novel candidate genes involved in the switch
between adipocyte and osteoblast differentiation and
confirmed their lineage-dependent transcriptional activa-
tion in human primary cells.
Results
hMADS cells represent a unique model for the study of 
adipogenesis and osteoblastogenesis
To characterize the hMADS cell model, quantitative RT-
PCR assays were performed for 33 selected genes using
RNA harvested at the reference time point and at the time
points 5, 7, and 8 for both differentiation pathways
(materials and methods).
Adipocyte differentiation of hMADS cells resulted in an
altered cell morphology as shown in Figure 1. Central
players of the adipogenesis-specific transcriptional net-
work including C/EBPβ, C/EBPδ, PPARγ2, C/EBPα, and
SREBP1c were found to be regulated in a differentiation-
dependent manner (see Additional file 1). In addition,
genes characteristic of the terminally differentiated phe-
notype were found to be up-regulated. These included
GPDH, HSL, FABP4, FABP5, PLIN, FASN (genes involved
in lipid metabolism), FXR (a regulator of cholesterol
homeostasis), GLUT4 (associated with systemic glucose
homeostasis), PEPCK (associated with adipocyte glycero-
neogenesis) and the genes encoding adipokines LEP, ADI-
POQ, CFD, TNFα, NAMPT, and RBP4 (see Additional file
1).
Osteoblastic differentiation of hMADS cells resulted in
calcium deposition in the extracellular matrix (Figure 1).
Transcriptional activators known to be expressed in the
osteogenic lineage including CBFA1 and MSX2 were con-
sistently up-regulated during osteoblast differentiation.
BMP4 and BMP6, members of the protein family that
induce bone formation at extracellular sites, and the BMP
receptors BMPR1B and BMPR2 were induced. Genes
involved in the development and homeostasis of the cal-
cification of the ECM including NOG, SPARC, OPG,
COL1A1, COL1A2, MGP, MATN3, and ESR1 (see Addi-
tional file 1) were also found to be up-regulated.
Hence, the normal karyotype, evidence for transcriptional
activation of the master regulators, and the biochemical
confirmation of the differentiated phenotypes, confirm
hMADS cells as a powerful model for the study of the adi-
pocyte/osteoblast balance.
Lineage-specific molecular processes are predominantly 
activated after commitment
Expression profiles were generated during differentiation
in both lineages and the expression data validated using
RT-PCR (see Additional file 2). 41 genes indicative for the
Adipocyte and osteoblast differentiation of hMADS cellsFigure 1
Adipocyte and osteoblast differentiation of hMADS cells. Time points for reference and sample harvesting are indi-
cated. Differentiation in both lineages was monitored including oil red O staining of lipid droplets in terminal adipocyte differ-
entiation and Alizarin red staining of calcium deposition in the extracellular matrix in terminal osteoblast differentiation.
75%  confl. 100 % adipocyte differentiation
75%  confl. 100 % osteoblast differentiation
ref tp1 tp2 3 tp4 tp5 tp6 tp7 tp8
d-3               d-2         d0 +8h   d+1      d+2                     d+5         d+10                                d+15 
sample harvest 
d-3               d-2         d0 +8h   d+1      d+2                     d+8         d+15                                d+24 
before after commitment
commitment
before after commitment
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lineage, and 37 genes potentially involved in self-renewal
with common expression profiles were studied. A high
degree of correlation was found (r2 = 0.81), similar to a
previous study [24], thus confirming the validity of the
microarray data. An overview of the expression profiles of
the differentiating cells and GO term analysis are pre-
sented in Figure 2A. A subset of genes which had at least
13 out of 16 present expression values (eight time points
per differentiation experiment) for both differentiation
studies were chosen for further analysis. Out of this sub-
set, a total of 1606 genes could be identified as signifi-
cantly differentially expressed after induction of
differentiation (see Methods section, Microarray data
analysis; see Additional file 2). These genes were clustered
according to adipogenic-related (ARG), osteogenic-
related (ORG), and differentiation-independent (DIG)
profiles in both lineages (Figure 2A). Our gene expression
data demonstrated an equal percentage of genes to be spe-
cifically regulated during adipocyte and osteoblast differ-
Differentially expressed genes and GO term analysisFigu  2
Differentially expressed genes and GO term analysis. A) Lineage-specific gene clustering. Shown is a clustering of 1,606 
genes to be more than twofold up- or down-regulated in at least one time point after differentiation induction. Genes were 
grouped into six fate-specific clusters, three with distinct profiles specific for adipogenesis, three with distinct profiles for oste-
oblastogenesis, and two fate-independent clusters with common profiles in both differentiation lineages. Relative expression 
levels (log2 ratios) for genes at different time points are shown and color coded according to the legend at the top (left) and 
expression profile (mean ± standard deviation) for each cluster (right). B) Distribution of differentially expressed genes for the 
three main clusters with adipogenesis-related (ARG), osteoblastogenesis-related (ORG), and differentiation lineage-independ-
ent (DIG) profiles. C)-D) Numbers of up-regulated and downregulated genes before and after commitment in both lineages. E) 
Distribution of significantly enriched GO terms for genes with adipogenic-related profiles (ARG: cluster 1–3) before and after 
commitment. F) Distribution of significantly enriched GO terms for genes with osteogenic-related profiles (ORG: cluster 4–6) 
before and after commitment. G) Distribution of significantly enriched GO terms for genes with differentiation-independent 
profile (DIG: cluster 7+8) before and after commitment.
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profile in both differentiation lineages (Figure 2B). A large
proportion of all 1606 differentially expressed genes were
found to be down-regulated (Figure 2C–D, see Additional
file 3).
hMADS cells have the ability to differentiate into adi-
pocytes or osteoblasts. After induction towards one of
these lineages, they retain the ability to be committed to
the other one by changing the differentiation medium
and cocktail for a limited time. A medium and cocktail
change at or later than time point 6 did not switch the dif-
ferentiation pathways indicating that the final and irre-
versible commitment to a given lineage takes place
between time points 5 and 6 (data not shown). We there-
fore analyzed the expression profiles between the early
stages of differentiation prior to commitment (time
points 3 to 5) and at the late stages of differentiation after
commitment (time points 6 to 8). Genes in each cluster
were sub-categorized according to their differential
expression before and/or after commitment.
In order to characterize the lineage-specific and lineage-
independent gene expression clusters, we categorized the
genes in each cluster with available RefSeq annotation
and Gene Ontology (GO) terms and extracted the GO
terms for biological processes which are significantly over-
represented (Figure 2E–G). Surprisingly, of the large
number of genes found to be differentially expressed dur-
ing both differentiation pathways, only a small number of
significantly enriched GO terms were found before com-
mitment. As expected, ARG are involved in metabolism,
fatty acid and lipid metabolism, fatty acid beta-oxidation, and
cholesterol biosynthesis and homeostasis.
Thus, although a large number of genes were found to be
differentially expressed during differentiation, lineage-
specific molecular processes were transcriptionally up-reg-
ulated only after commitment.
Predominant gene repression before commitment in 
adipocyte and osteoblast differentiation pathways
Genes involved in the hematopoietic system, angiogenesis, B-
cell differentiation and epithelial to mesenchymal transition
were repressed during adipocyte differentiation, (cluster
3). Interestingly, genes involved in notch signaling, whose
down-regulation is commonly considered to be a prereq-
uisite for the adipogenic pathway, were significantly
enriched [1]. This gene repression appeared exclusively
before commitment to the adipogenic lineage.
During osteoblast differentiation, the GO terms protein
biosynthesis, regulation of translational initiation, and
response to unfolded protein were enriched by genes
repressed before and after commitment (cluster 6). Inter-
estingly, only protein folding was found to be down-regu-
lated after commitment, whereas response to heat, protein
catabolism, regulation through cell cycle, anion transport, actin
filament organization, RNA splicing and cellular morphogene-
sis were repressed before commitment to the osteogenic
lineage.Glycolysis was statistically over-represented for
genes down-regulated before and after commitment,
whereas DNA replication only after commitment (cluster
8).
Taken together, the results show that the majority of genes
were down-regulated, with this down-regulation occur-
ring both before and after commitment. Down-regulated
genes were predominant prior to commitment for genes
in all of the three main categories, ARG, ORG, and DIG.
On the other hand, the number of up-regulated genes
doubled from early to late differentiation stages.
Computational analyses reveal that miRNA targeting 
corresponds with prevalent down-regulation of genes 
before commitment
We have recently shown that during adipogenesis a large
number of mRNAs might be potential targets for microR-
NAs (miRNAs) [24]. miRNAs are an abundant class of
endogenous, small non-coding RNAs (19–25 nucle-
otides) that negatively regulate gene expression at the
post-transcriptional level by base pairing with the 3'-
untranslated region (3'-UTR) of target messenger RNAs.
Several studies have demonstrated the involvement of
miRNAs in gene regulation, metabolism, cell differentia-
tion, and development [25-30]. Well over one third of
mammalian genes appear to be conserved miRNA targets
[31]. Rules for target recognition, for instance the seven-
nucleotide (7-nt) miRNA seed sequence, defined as posi-
tions 2–8 at the 5' end of the miRNA, combined with fea-
tures of site context, were applied to predict and discover
human miRNA targets [31,32].
We performed a miRNA binding site analysis to identify
miRNAs potentially targeting genes regulated during adi-
pocyte or osteoblast differentiation and significantly over-
represented miRNA targets in the eight distinct gene clus-
ters. Out of the 1606 genes identified as being differen-
tially expressed during differentiation the 3'-UTR
sequence could be obtained for 1147 of them. All of these
had at least one exact antisense match with the 7-nt seed
(base 2–8 at the 5' end) from the 470 human miRNA
sequences (19–25 base pairs). 915 genes (79.8%) had at
least one match for significantly over-represented miRNAs
whose 7-nt seed exactly matched only to 16844 genes
(71.3%) among the entire 23.611 3'-UTR sequence set.
The distribution of statistically enriched 3'-UTR miRNA
motifs varied across the clusters, with genes in cluster 1
having no detectable motifs and genes in cluster 5 having
the most miRNA motifs. In summary, 80% of all genesPage 5 of 14
(page number not for citation purposes)
BMC Genomics 2008, 9:340 http://www.biomedcentral.com/1471-2164/9/340with a unique 3'-UTR that were differentially expressed
during adipocyte and osteoblast differentiation are poten-
tial targets for 30 miRNAs with significantly over-repre-
sented motifs (see Additional file 5).
We performed the analysis of significantly over-repre-
sented miRNA binding sites for genes regulated before
and after commitment for both differentiation pathways.
Within all clusters, we found that the ratio of the number
of genes containing a miRNA seed match in the 3'-UTR
before and after commitment was comparable with the
ratio for all genes regulated before and after commitment
in a cluster (see Additional file 4).
Novel candidate genes for the lineage commitment 
revealed by gene expression and promoter analyses
Genes that are differentially expressed at a specific time
point may be involved in lineage commitment. We there-
fore extracted genes that were differentially expressed
from time points 5 to 6 specifically in one differentiation
pathway. In support of the time point selection, we found
TAZ, a known transcriptional coactivator of bone devel-
opment and repressor of adipocyte differentiation [34],
derepressed at the time of commitment in osteoblast-
ogenesis, but with delay in adipogenesis after the commit-
ment. 26 genes regulated in this manner were identified
for the adipogenic lineage and 39 for the osteogenic line-
age (Figure 3). Interestingly, each cluster contained a
nuclear receptor: NR1H3 (liver X receptor alpha; LXRα)
for adipogenic commitment, and NR2F1 (chicken ovalbu-
min upstream promoter transcription factor 1; COUP-
Genes differentially expressed during commitment between time point 5 and 6Figure 3
Genes differentially expressed during commitment between time point 5 and 6. A) 26 genes specifically up-regu-
lated between time point 5 and 6 during adipocyte differentiation. B) 39 genes specifically up-regulated between time point 5 
and 6 during osteoblast differentiation.Page 6 of 14
(page number not for citation purposes)
BMC Genomics 2008, 9:340 http://www.biomedcentral.com/1471-2164/9/340TF1), an orphan nuclear receptor acting predominantly as
a transcription repressor [35] for osteogenic commitment.
To examine co-regulation, we screened the promoter
sequences available for these 65 genes for statistically
over-represented transcription factor binding sites (TFBS).
Significantly enriched TFBS were found in both gene clus-
ters. For adipogenesis the promoters of 26 genes had over-
represented TFBS for 20 transcription factors and for
osteoblastogenesis promoters of 39 genes had overrepre-
sented TFBS for 11 transcription factors. (see Additional
files 6 + 7). In the adipogenic commitment cluster, six
genes were found to contain the PPARγ DR1 response ele-
ment and two genes to contain an LXR response element,
providing evidence for the potential co-regulation of these
co-expressed genes. Strikingly, seven adipogenic-related
genes were found to contain a COUP-TF1 binding site
with the highest significance. In a reciprocal manner, five
genes in the osteogenic commitment cluster contained a
binding site for SREBP, a transcription factor also found to
be up-regulated during early adipogenesis.
During adipogenic commitment, we identified the phos-
pholipid transfer protein (PLTP), an important molecule
in the regulation of phospholipid, cholesterol and HDL
metabolism [36]. Interestingly, the computational analy-
sis of the promoter of PLTP showed a KROX response ele-
ment (see Additional file 4, significant rank #3). During
the osteogenic commitment, the hypothetical protein
FLJ22104 (TMEM135) was found to contain 11 signifi-
cantly enriched TFBS, the highest number of TFBS in a
given gene an representing more than 50% of all signifi-
cant TFBS found. Based on the results of in-depth protein
sequence analysis, TMEM135 is a multi-transmembrane
protein with 7 transmembrane helices of high confidence.
The N-terminal transmembrane region (3 helices) and the
C-terminal region (4 helices) are separated by a mixed
charged cluster (amino acid (aa): 200–250)) with a high
KRED content (43%). Homologies exist with the trans-
membrane region of similar to frizzled 4 (XP_788346; aa:
153–447; E-value = 1E-53), a component of the Wnt sig-
naling pathway [37]. Less extensive homologies exist to
peroxisomal protein 4 (NP_757377; E-value = 6E-37; 5th
psi-blast round) and TIM17 (pfam02466; rps-blast E-
value = 0.028), a mitochondrial translocator.
Validation studies on selected candidate genes
The 4 selected candidate genes, LXRα, PLTP (adipogene-
sis), COUP-TF1 and TMEM135 (osteoblastogenesis), were
subjected to additional validation experiments. Western
blot analysis of the supernatant from differentiating
hMADS after 3 days in culture revealed that PLTP is
secreted during adipocyte differentiation but not during
osteoblast differentiation (Figure 4). After two weeks, the
protein expression levels were very high in the adipocyte
culture medium whereas a lower level was detected in the
osteoblast culture medium suggesting that adipocytes
secreted PLTP more than osteoblasts.
To obtain validation data for the other candidate genes,
primary hMSC obtained from healthy donors were differ-
entiated and expression levels analyzed by RT-PCR (Figure
5). COUP-TF1 exhibited higher expression levels during
osteoblastogenesis. The expression level of COUP-TF2
was the same in both cell models and differentiation lin-
eages (data not shown). LXRα was expressed at an eight-
fold higher level in adipocytes than in osteoblasts and
TMEM135 expression was on average 2-fold higher in adi-
pocytes than in osteoblasts.
This data provide additional evidence for an involvement
of the selected candidate genes, PLTP, LXRα, COUP-TF1,
and the transmembrane protein TMEM135 respectively in
adipocyte and osteoblast differentiation. PLTP was
secreted at both early and late time points of adipocyte
differentiation of hMADS. LXRα, COUP-TF1, and
TMEM135 were transcriptionally activated in differentiat-
ing bone marrow stromal cells from healthy donors in a
lineage-dependent manner.
Discussion
In this study we have used a unique model and large-scale
gene expression profiling to study the transcriptional reg-
ulation of biological processes occurring during the differ-
entiation of multipotent stem cells. The data presented
here and the bioinformatics analyses considerably aug-
ment previous studies of early adipocyte and osteoblast
differentiation. Our comprehensive and unbiased
approach resulted in the identification of 1606 differen-
tially expressed genes and suggests several important bio-
logical conclusions.
Firstly, the gene down-regulation was most prevalent in
both adipogenesis and osteoblastogenesis. The extent of
PLTP secretion during differentiation of hMADS cells to adi-pocytes and osteoblastsFigur  4
PLTPsecretion during differentiation of hMADS cells 
to adipocytes and osteoblasts. The expression of PLTP in 
the secretion media of hMADS cells at day 0, and during dif-
ferentiation at days 3 and 14 adipocytes (HAD) or osteob-
lasts (HOD) after 6 h of incubation.
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RT-PCR results for COUP-TF1, LXRα, and TMEM135 during adipogenesis and ostoblastogenesis from bone marrow stromal cells from healthy donorsFigure 5
RT-PCR results for COUP-TF1, LXRα, and TMEM135 during adipogenesis and ostoblastogenesis from bone 
marrow stromal cells from healthy donors.
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BMC Genomics 2008, 9:340 http://www.biomedcentral.com/1471-2164/9/340gene repression varied before and after commitment and
was more pronounced in osteoblastogenesis. Surpris-
ingly, GO term analysis showed that only few significantly
enriched biological processes were transcriptionally up-
regulated prior to commitment. This contrasts with our
previous study in which many molecular processes were
found to be modulated [24]. The results of the current
study suggest that repression of diverse sets of genes is a
general phenomenon during early differentiation of stem
cells. It is also tempting to speculate that committed cells
can undergo transdifferentiation because of the lack of
activation of specific cellular processes. It has been shown
for example that white adipocytes can be transdifferenti-
ated to brown adipocytes [3]. Further studies are necessary
to identify both the length of the time window for the
transdifferentiation and the appropriate stimuli.
Secondly, computational analyses of the 3'UTR of the dif-
ferentially expressed genes support the hypothesis that
gene repression is modulated by miRNAs. Several miR-
NAs have been shown to affect late stages of adipocyte dif-
ferentiation, and the expression of other miRNAs has
been reported during osteoblast differentiation [38-41].
Here we provide data showing that miRNAs might be
involved in gene regulation during the early stages of both
lineages. Using conservative criteria for the miRNA bind-
ing sites, over 80% of the genes with unique 3'UTR were
found to contain at least one exact antisense match for the
7-nt seed and are thus potential target for 30 miRNAs.
Although the number of false positives in this analysis is
difficult to estimate, it is likely that many miRNAs repress
a large number of genes. This observation has implica-
tions for therapeutic targeting using antisense strategies.
Further studies will be required to identify the most prom-
ising candidates.
Thirdly, gene expression data and promoter analysis of
the differentially expressed genes identified 26 that may
play a role in adipogenic and 39 in osteoblastogenic com-
mitment. From these, we selected four candidates: LXRα,
and PLTP for adipogenesis, and COUP-TF1 and
TMEM135 for osteoblastogenesis. Validation studies pro-
vided additional evidence that these genes are involved in
determining the balance between adipocyte and osteob-
last differentiation.
The nuclear hormone receptor and transcription factor,
LXRα, is known to play a major role in the regulation of
cholesterol catabolism, inflammatory gene expression
and the switch between glucose metabolism and fatty acid
synthesis [42-44]. PLTP is believed to be a direct target
gene of LXRs which is consistent with our results demon-
strating specific activation of LXRα and PLTP at the time
of commitment and secretion of PLTP in a differentiation-
dependent manner [45]. The finding that PLTP contains a
KROX response element as a significantly enriched TFBS
and the very early transcriptional up-regulation of PLTP
compared to LXRα however indicates that PLTP is also
activated by additional, LXRα-independent regulatory
mechanisms.
Our finding that COUP-TF1 is transcriptionally activated
at the time of osteogenic commitment is consistent with
loss of function studies in mice revealing bone fusion in
occipital bones in 98% of the null mutants [46]. Tran-
scriptional repression by the orphan receptor COUP-TF1
is known to play a critical role in several developmental
processes including neurogenesis, angiogenesis and heart
development [35]. Strikingly, we identified its binding
site in seven genes of the adipogenic commitment cluster
with the highest significance suggesting a major role of
COUP-TF1 in lineage commitment involving suppression
of adipogenic and promotion of osteogenic differentia-
tion. Interestingly, in a recent study it was shown that
COUP-TF2 suppresses adipogenesis [47]. It should be
noted that in this study committed mouse cells were used
whereas in our study uncommitted human cells were
investigated. Given this experimental evidence in differing
species and commitments, and the high degree of similar-
ity to binding sites for the COUP-TFs, we hypothesize that
the orphan nuclear receptor family COUP-TF are critical
regulators of adipogenesis and osteoblastogenesis. The
identification of exogenous COUP-TF ligands will enable
the exploration of therapeutic opportunities involving
modulation of COUP-TF.
Finally, we have also investigated the role of TMEM135, a
gene previously identified in a human lung adenocarci-
noma cell line cDNA library [48] in osteogenesis. Based
on its sequence structure and homologies with other gene
products, TMEM135 is likely to be a channel (charged
cluster in the middle) or a receptor (charged cluster to the
surface). With the highest number of significantly
enriched TFBS, e.g. for COUP-TF1, PPARγ, KROX, GATA-3,
and LXR, TMEM135 is an interesting candidate for
involvement in lineage commitment, an hypothesis that
must nevertheless be validated by further studies.
In conclusion, our study on gene expression signatures
during adipogenic and osteoblastogenic differentiation of
hMADS cells showed common global transcriptional pat-
terns for both lineages. Our results reveal gene repression
as a predominant early mechanism before final cell com-
mitment indicating that gene repression may have a larger
functional role in controlling the cell fate. This repression
is likely to be controlled by miRNAs. We were moreover
able to identify 65 genes as candidates for genes control-
ling the adipocyte/osteoblast balance and to further eval-
uate four of these. Additional studies will explore thePage 9 of 14
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pogenesis/osteoblastogenesis switch.
Methods
hMADS cell culture
hMADS cells were grown in Dulbecco's Modified Eagle's
Medium (DMEM low glucose) containing 10% fetal calf
serum (FCS), and 100 U/ml penicillin and streptomycin.
After reaching 80% confluence, adherent cells were
detached with 0.25% trypsin EDTA and seeded at a den-
sity of 4500 cells per cm2. hMADS cells were maintained
in proliferation medium supplemented with 2 ng/ml
fibroblast growth factor 2 (FGF2) [21].
For adipocyte differentiation, two days after confluence
(referred to as day 0), cells were cultured in DMEM/Ham's
F12 medium supplemented with 10 μg/ml transferrin,
0.86 μM insulin, 0.2 nM of triiodothyronine, 1 μM dex-
amethasone, 100 μM isobutyl-methylxanthine, and 100
nM rosiglitazone. Three days later, the medium was
changed (dexamethasone and isobutyl-methylxanthine
were omitted). Neutral lipid accumulation was assessed
by oil red O staining as described previously [49].
For osteoblast differentiation, cells were cultured for 24
days in α-MEM containing 10% FCS, 50 μg/ml L-ascorbic
acid phosphate, 10 mM β-glycerophosphate, and 100 nM
dexamethasone. Alizarin red staining was performed as
previously described [50]. All media were changed every
other day.
hMSC cell culture
The mononuclear cell fractions were derived from bone
marrow from four donors who gave consent after full
information and approval by the hospital ethical commit-
tee (No. 12-091). hMSC were grown in Dulbecco's modi-
fied Eagle's medium (high glucose) containing 10% fetal
bovine serum PAN, 2 mM L-glutamine, 100 U/ml penicil-
lin and streptomycin, 100 μg/ml normocin (InvivoGen)
under standard conditions. Adipocyte differentiation was
induced on the third day after the cells reached confluence
with medium containing 1 μM dexamethasone, 0.5 mM
isobutylmethylxantine, 60 μM indomethacine, 1 μM ros-
iglitazone and 10 μg/ml insulin. After 2–3 days the cells
were refed with medium was containing only 10 μg/ml
insulin for a period of 24 h. This cycle was repeated a total
of 3 times. During the final 7 days of differentiation the
cells were cultured in medium containing 10 μg/ml insu-
lin. Differentiation was confirmed by oil red O staining.
Osteoblast differentiation was triggered 24 h after cell
seeding with medium containing 0.1 μM dexamethasone,
10 mM glycerophosphat and 100 mM L-ascorbic acid
phosphate. The different time period compared to
hMADS is due to the differences of the origins of cells
(adipose tissue vs. bone marrow) and the differences in
the the cultivation media. The medium was changed 2–3
times a week over a total period of 21 days. Differentia-
tion was confirmed by alizarin red staining.
Sample preparation and microarray hybridization
Three independent cell culture experiments were per-
formed as biological replicates for both adipocyte and
osteoblast differentiation. Cells were harvested at the pre-
confluent stage as reference and at eight subsequent time
points (adipocyte differentiation: day -2 (tp1) and 0 (tp2)
before differentiation induction, and 8 hours (tp3), 1
(tp4), 2 (tp5), 5 (tp6), 10 (tp7), and 15 days (tp8) after
induction of differentiation; osteoblast differentiation:
day -2 (tp1) and 0 (tp2) before differentiation induction,
and 8 hours (tp3), 1 (tp4), 2 (tp5), 8 (tp6), 15 (tp7), and
24 days (tp8) after induction of differentiation). For each
time point of each independent experiment RNA was
pooled from 6 different 100 mm culture dishes. Reference
RNA was harvested from 48 dishes of cells at the precon-
fluent stage.
Total RNA was isolated using TRIzol reagent (Invitrogen,
Carlsbad, CA, USA) or Tri-Reagent (Euromedex, Mun-
dolsheim, France) according to the manufacturer's
instructions. The quality of the RNA was checked using
Agilent 2100 Bioanalyzer RNA assays (Agilent Technolo-
gies, Palo Alto, CA, USA). 20 μg of total RNA was used for
indirect labeling with Cy3 and Cy5. Human microarrays
spotted with 29550 oligonucleotides and the represented
genes identified with RefSeq IDs were produced and
hybridized as previously described [51]. All hybridiza-
tions were repeated with reversed dye assignment (dye-
swap). Hybridized slides were scanned with a GenePix
4000B microarray scanner (Axon Instruments, Sunnyvale,
CA, USA) at 10 μm resolution and the resultant TIFF
images analysed with GenePix Pro 4.1 software (Axon
Instruments).
Real-time RT-PCR
41 genes indicative for the adipogenic lineage, 22 genes
indicative for the osteogenic lineage, and 37 genes poten-
tially involved in self-renewal have been validated by
reverse transcription polymerase chain reaction (RT-PCR)
analysis of total RNA as described previously [20]. An
aliquot of the PCR product was analyzed on a 2% ethid-
ium bromide-stained agarose gel. For quantitative PCR,
the final reaction volume was 25 μl, including specific
primers (0.2–0.4 μM), 5–12 ng of reverse-transcription
product and 9–12.5 μl of SYBR green master mix (Euro-
gentec, Angers, France). Quantitative PCR was carried out
as follows: 2 minutes at 50°C; 10 minutes at 95°C; and 35
cycles of 15 seconds at 95°C and 1 minute at 60°C. Real-
time PCR assays were run on an ABI Prism 7000 real-time
PCR machine (Applied Biosystems, Foster City, CA, USA).Page 10 of 14
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ence). Relative expression was calculated with the ddCt
method [52].
Western blotting
After 6 hours of incubation for each condition, secretion
media (6 ml, corresponding to 2 dishes of 100 mm diam-
eter) were collected on ice, centrifuged, filtered to remove
cell debris and supplemented with complete protease
inhibitor cocktail. The samples were concentrated before
analysis by ultra-filtration (Millipore, Centricon, 5 kDa
cut-off). Equal volumes of secretion media were separated
by SDS-PAGE, transferred to PVDF membrane and proc-
essed for the expression of PLTP using specific anti-human
antibodies (provided by M. Jauhiainen) [53]. Immunore-
active signal was visualized with the ECL chemilumines-
cence detection kit (Amersham) according to the
manufacturer's instructions.
RNA isolation
Cells were collected in TRIzol (Invitrogen) before and 24
h, 48 h, 5, 10, 15, 21 days after differentiation induction.
Total RNA was isolated according to the manufacturer's
instructions. The quality of the RNA was examined using
Agilent 2100 Bioanalyzer RNA assays (Agilent Technolo-
gies).
Microarray data analysis
Global mean and dye swap normalization were applied
using ArrayNorm [54]. The resulting ratios were log2
transformed and averaged over three independent experi-
ments. All experimental parameters, images, and raw and
transformed data were uploaded to the microarray data-
base MARS [55] and submitted via MAGE-ML export to a
public repository (ArrayExpress [56], accession number A-
MARS 3 and E-MARS 10).
Statistical analysis
The aim was to identify genes with a significant change in
expression before induction (tp1 and tp2) compared to
the expression level after induction (time points 3 to 8).
To that end we calculated the difference in expression
between time point 1 and all time points after induction
(tp3.tp8), and the same was done for time point 2. For
each gene, we considered the maximum of all these differ-
ences (in absolute values) as an estimate of its change in
expression before and after induction. If that log-ratio was
larger than +/-1 (2 fold change) we consider the gene as
differentially expressed after differentiation induction. We
categorized these differentially expressed genes according
to the following profiles: a) Opposite expression, b) line-
age-specific expression and c) similar expression in the
adipocyte and osteoblast differentiation pathways. For
those genes differentially expressed in either HAD or
HOD experiments, the Pearson correlation coefficient
(scale-invariant) was calculated and its significance was
assessed using the permutation test implemented in the R
permax package http://www.r-project.org. This analysis
yielded a total of eight clusters: three for adipogenic-
related genes (ARG) (HAD-HOD; 1: up-down; 2: up-non;
3: down-non), three clusters for osteogenic-related genes
(ORG) (HAD-HOD; 4: down-up; 5: non-up; 6: non-
down), and two clusters for differentiation-independent
genes (DIG) (HAD-HOD; 7: up-up; 8: down-down).
Gene Ontology classification
Gene Ontology (GO) terms for biological processes were
derived from the Gene Ontology database (Gene Ontol-
ogy Consortium) using the RefSeq accession numbers. All
cluster analyses and visualizations were performed using
Genesis [57].
Identification of miRNA target sites in the 3'-UTR
All available 3'-UTR sequences (23,611) for human genes
were extracted using the human genome version hg18
(NCBI build 36.1) from the USCS Genome Browser [58]
and genomic coordinates for human genes from the Ref-
seq database [59]. A total of 470 human miRNA
sequences were derived from mirBase [60]. The 3'-UTR
sequences were searched for perfect antisense matches to
the designated seed region of each miRNA (bases 2–8
from the 5' end). Significantly over-represented miRNA
motifs in the 3'-UTRs of genes in each cluster and for the
full set of differentially regulated genes that were signifi-
cantly over-represented compared with the motifs in the
whole 3'-UTR sequence set were determined using the
one-sided Fisher's exact test (p < 0.05). To account for
multiple testing p-values were adjusted controlling for the
false discovery rate (FDR < 5%) as proposed by Benjamini
and Hochberg [61].
Promoter analysis
Promoter analysis was performed using CRSD, a compre-
hensive web server for composite regulatory signature dis-
covery [62]. Iterative enrichment analysis was conducted
based on putative promoter and TRANSFAC databases.
Transcription factor binding sites were selected as statisti-
cally over-represented with a significance level of the cor-
rected P-value < 0.1.
Protein domain analysis
Protein sequences were annotated de novo using the more
than 40 prediction tools that are integrated in the ANNO-
TATOR, a novel protein sequence analysis system includ-
ing composition, TM region, motif and homology
analysis [63,64].
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